<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769037</url>
  </required_header>
  <id_info>
    <org_study_id>GPPAD-04</org_study_id>
    <nct_id>NCT04769037</nct_id>
  </id_info>
  <brief_title>Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity</brief_title>
  <acronym>SINT1A</acronym>
  <official_title>&quot;SINT1A&quot; - Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity - A Study of the Global Platform for the Prevention of Autoimmune Diabetes (&quot;GPPAD&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinderkrankenhaus auf der Bult</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge Biomedical Campus, Cambridge, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Victoria Infirmary, Newcastle upon Tyne, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helmholtz Zentrum München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator initiated, randomised, placebo-controlled, double-blind, multi-centre primary&#xD;
      intervention study to assess whether daily administration of B. infantis EVC001 from age 7&#xD;
      days to 6 weeks (+14 days) until age 12 months (+ 14 days) to children with elevated genetic&#xD;
      risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies in&#xD;
      childhood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GPPAD-04 SINT1A study will evaluate whether early, regular supplementation with a daily&#xD;
      dose of a probiotic can reduce the risk of developing beta-cell autoimmunity in children&#xD;
      identified by GPPAD-02 as being genetically predisposed to developing type 1 diabetes.&#xD;
      Children will be enrolled at age 7 days to 6 weeks (+14 days) and the study product (B.&#xD;
      infantis EVC001 or Placebo) will be administered orally once per day from enrollment until&#xD;
      age 12 months (+14 days).&#xD;
&#xD;
      The hypotheses is that administration of B. infantis may have a positive influence on the&#xD;
      intestinal flora and thus have a regulating effect on the immune system. The study is&#xD;
      designed to investigate whether pathogenic immune reactions as in type 1 diabetes but also in&#xD;
      other diseases, such as celiac disease, can be reduced and if the disease can be prevented.&#xD;
&#xD;
      Children will be followed until age 3.5 - 6.5 years (2.5 - 5.5 years after end of treatment).&#xD;
&#xD;
      Throughout the study data will be collected by regular study visits, phone calls with the&#xD;
      families and electronic questionaires.&#xD;
&#xD;
      Blood samples will be collected to investigate glucose, HbA1c, beta-cell autoantibodies,&#xD;
      transglutaminase antibodies, vaccine responses, genetic susceptibility and mechanistic&#xD;
      markers. Stool samples will be collected for further assessments such as&#xD;
      colonization,microbiome, pH and calprotectin.&#xD;
&#xD;
      Exploratory outcomes (allergy, vaccine responses, stool microbiome, blood metabolomics, stool&#xD;
      pH and calprotectin or site specific ancillary measurements) may be assessed or in part&#xD;
      assessed on a portion of the participants after unblinding the study. They may not&#xD;
      necessarily be included in the primary outcome analysis and publication.&#xD;
&#xD;
      GPPAD is committed to sharing of data in compliance with all applicable European and GPPAD&#xD;
      Consortium Member State, Data Protection and Privacy Protection laws, rules and regulations.&#xD;
&#xD;
      Pseudonymized data of the GPPAD-04 SINT1A study will be available to the scientific community&#xD;
      after the publication of the trial analysis, which is anticipated in 2028. The SINT1A data&#xD;
      will be available upon request.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Persistent confirmed multiple beta-cell autoantibodies</measure>
    <time_frame>Through study completion, up to 6.5 years</time_frame>
    <description>Persistent confirmed multiple beta-cell autoantibodies is defined as confirmed IAA, confirmed GADA, confirmed IA-2A, or confirmed ZnT8A in two consecutive samples, AND a confirmed second antibody from these four antibodies in one sample.&#xD;
The primary outcome is the elapsed time from the random treatment assignment to the first confirmed autoantibody positive sample used in defining the persistent confirmed multiple beta-cell autoantibody positive status. Diabetes in the absence of multiple beta-cell autoantibodies is also considered as a primary outcome endpoint, and in this case, the date of diagnosis is the time of the end point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistent confirmed beta-cell autoantibodies</measure>
    <time_frame>Through study completion, up to 6.5 years</time_frame>
    <description>Any persistent confirmed beta-cell autoantibody, defined as at least one confirmed autoantibody in two consecutive samples, including IAA, GADA, IA-2A or ZnT8A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes</measure>
    <time_frame>Through study completion, up to 6.5 years</time_frame>
    <description>Criteria for T1D onset are, as defined by the American Diabetes Association (ADA), based on glucose testing, or the presence of unequivocal hyperglycaemia with acute metabolic decompensation (diabetic ketoacidosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transglutaminase antibodies</measure>
    <time_frame>Through study completion, up to 6.5 years</time_frame>
    <description>Transglutaminase antibodies defined as persistent in two consecutive samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory infection rate</measure>
    <time_frame>1 year</time_frame>
    <description>Respiratory infection rate in first year of life during supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Safety parameters</measure>
    <time_frame>from Baseline until 30 days after end of supplementation</time_frame>
    <description>Adverse Events and Serious Adverse Events will be captured until 30 days after the last administration of the food product.&#xD;
Local and systemic adverse effects will be elicited by direct questioning of the participant or parent. Systemic effects will be sought by questioning about any untoward symptoms or signs, and graded as mild, moderate, severe, life-threatening or death according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Allergy</measure>
    <time_frame>Through study completion, up to 6.5 years</time_frame>
    <description>Participant's parents will be asked to complete questionnaires to obtain information about allergies every 12 months. Analyses will compare the B. infantis supplementation and placebo groups for the frequency of allergy and allergy sub-groups as defined form the yearly questionnaires.</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody response (IgG titres) to vaccines</measure>
    <time_frame>at age 6 months (rotavirus) and at age 2 years (MMR)</time_frame>
    <description>Information about rotavirus and MMR vaccination will be collected from parents and antibody response (IgG titers) will be measured centrally.</description>
  </other_outcome>
  <other_outcome>
    <measure>Alterations of the gut microbiome or blood metabolome</measure>
    <time_frame>from baseline to age 12 months</time_frame>
    <description>Exploratory analyses will examine the associations between B. infantis supplementation and mouth and stool organisms (microbiome), and blood markers such as the metabolome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool pH</measure>
    <time_frame>at age 6 months</time_frame>
    <description>Stool pH levels will be compared between B. infantis supplementation and placebo groups in a subset of children</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool calprotectin</measure>
    <time_frame>at age 6 months</time_frame>
    <description>Stool calprotectin levels will be compared between B. infantis supplementation and placebo groups in a subset of children</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1144</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>B. infantis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose identical in appearance and taste to the active supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B. infantis</intervention_name>
    <description>Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day</description>
    <arm_group_label>B. infantis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose identical in appearance and taste to the active supplement</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infants between the ages of 7 days and 6 weeks (+14 days in case of illness or&#xD;
             COVID-19 related issues or unexpected delay in result reporting) at the time of&#xD;
             randomisation.&#xD;
&#xD;
          2. A 10% or higher genetic risk to develop multiple beta-cell autoantibodies by age 6&#xD;
             years:&#xD;
&#xD;
               1. For infants without a first-degree family history of type 1 diabetes, high&#xD;
                  genetic risk is defined as a DR3/DR4-DQ8 or DR4-DQ8/DR4-DQ8 genotype and a&#xD;
                  genetic risk score that is in the upper 25th centile (&gt;14.4) or a DR3/DR4-DQ8&#xD;
                  genotype with a GRS between the upper 50th (14.0) and 25th centile and a GG&#xD;
                  genotype at the rs3763305 SNP. These represent around 1% of all newborns.&#xD;
&#xD;
               2. For infants with a first-degree family history of type 1 diabetes, high genetic&#xD;
                  risk is defined as having HLA DR4 and DQ8, and none of the following protective&#xD;
                  alleles: DRB1*1501, DQB1*0503, DRB1*1303. These represent around 30% of infants&#xD;
                  with a first-degree family history of T1D.&#xD;
&#xD;
          3. Written informed consent signed by the custodial parent(s).-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any medical condition, concomitant disease or treatment that may interfere with the&#xD;
             assessments or may jeopardize the participant's safe participation in the study, as&#xD;
             judged by the Investigators.&#xD;
&#xD;
          2. Preterm delivery &lt; 36 weeks of gestation.&#xD;
&#xD;
          3. Proven immunodeficiency.&#xD;
&#xD;
          4. Any condition that could be associated with poor compliance.5. Diagnosis of diabetes&#xD;
             at the time of recruitment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anette-G. Ziegler, Prof. Dr.</last_name>
    <phone>+49-(0)800-000</phone>
    <phone_ext>0018</phone_ext>
    <email>contact@gppad.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Achenbach, Prof. Dr.</last_name>
    <phone>+49-(0)800-000</phone>
    <phone_ext>0018</phone_ext>
    <email>contact@gppad.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven Faculty of Medicine, Catholic University of Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Casteels, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Technische Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Berner, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUF DER BULT, Kinder- und Jugendkrankenhaus</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Kordonori, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Diabetes Research, Helmholtz Zentrum Munich, Germany, and Forschergruppe Diabetes, Technical University Munich (TUM), School of Medicine, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette-G. Ziegler, Prof.Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Szypowska, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University, Skane University Hospital SUS</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Lundgren, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Department of Paediatrics, Cambridge Biomedical Campus</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Loredana Marcovecchio, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary, Newcastle upon Tyne</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Owen, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gppad.org/en/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helmholtz Zentrum München</investigator_affiliation>
    <investigator_full_name>Anette-Gabriele Ziegler</investigator_full_name>
    <investigator_title>Director - Institute of Diabetes Research</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes autoimmunity</keyword>
  <keyword>celiac autoimmunity</keyword>
  <keyword>respiratory infections</keyword>
  <keyword>allergy</keyword>
  <keyword>prevention</keyword>
  <keyword>probiotic</keyword>
  <keyword>B. infantis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>GPPAD is committed to sharing of data in compliance with all applicable European and GPPAD Consortium Member State, Data Protection and Privacy Protection laws, rules and regulations.&#xD;
Pseudonymized data of the GPPAD-04 SINT1A study will be available to the scientific community after the publication of the trial analysis, which is anticipated in 2028. The SINT1A data will be available upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

